Tagged with IT

Europe Ophthalmology is a booming niche, with investment flowing in, M&A up, and a burgeoning cast of biotechs – including the three European leaders profiled below – vying for a share of a global market set to top USD 93.7 billion by 2030   The field can already boast two bona-fide…

France France is considered among the leading rare disease markets worldwide, both scientifically and organisationally. The country has cultivated a fully-fledged supporting ecosystem for rare conditions that is today regarded as a benchmark internationally, and which few other countries have proven able to match.   “Back in the mid-2000s, under the…

France France’s historical contribution to medical research is almost unparalleled globally, with 13 winners of the annual Nobel Prize for Physiology or Medicine, and even more for Chemistry. Most famously, Louis Pasteur’s work on germ theory and pasteurisation in the 19th century laid the groundwork for much of what we know…

France France may have ceded Europe’s top spot for the sheer number of clinical trial starts to Spain in 2023, but it remains one of Europe’s most strategically valuable destinations for complex, high-science clinical research. In oncology and rare diseases clinical R&D especially, France punches well above its weight, supported by…

Global Andrea Johnston,* Senior Phorum Director at BioPhorum,** argues that the biopharma industry’s rapid embrace of digital twins is being undermined by a fundamental problem: agreeing what a digital twin actually is. Drawing on fresh benchmarking data from leading manufacturers, Johnston contends that this lack of shared definition is slowing regulatory…

Taiwan Chung-Liang Shih, Taiwan’s Minister of Health and Welfare, brings extensive governmental experience from his tenure as Director General of the National Health Insurance Administration, where he led reforms to strengthen financial sustainability while expanding access to innovative medicines. His strategic vision focuses on structural healthcare reform, digital transformation, and preventative…

USA John Murphy III, President and CEO of the Association for Accessible Medicines (AAM), argues that 2026 represents a pivotal moment for the United States to reclaim leadership in biosimilars. He outlines how recent FDA reforms could finally unlock competition, lower drug costs, and expand patient access, while warning that outdated…

USA Genome editing is moving from proof of concept to clinical reality, but questions around scale, cost, and responsibility now define its future. In this interview, Brad Ringeisen outlines how the Innovative Genomics Institute is shaping CRISPR as a platform for real-world impact, bridging philanthropy, academia, and industry while navigating regulation,…

Taiwan Taiwanese biotech Caliway is trying to redefine fat reduction as measurable medicine. Founded in 2012, Caliway has advanced its first-in-class candidate CBL-514 into pivotal Phase III development in the US, following ten completed clinical studies. President Antony Hsu outlines the science behind selective adipocyte apoptosis, the regulatory strategy behind the…

Europe Writing in the January 2026 edition of DIA’s Global Forum, Samantha Holmes and Fiona Adshead of the Sustainable Healthcare Coalition argue that climate change is already reshaping healthcare and the medicines life cycle, while the pharma sector itself contributes materially to global emissions. Against this backdrop, the European Medicines Agency…

Taiwan In 2024, Taipei Medical University reached a defining milestone. President Mai-Szu Wu oversaw a full digital transformation linking seven affiliated medical institutions and more than 3,000 beds into a unified data platform, creating a foundation for large-scale research, AI applications, and faster clinical-trial operations. This momentum has now extended nationwide…

LatAm Carlos Abelleyra leads Medix, a 70-year-old Mexican pharmaceutical company undergoing a major strategic transformation. Since 2024, he has diversified the firm beyond its historical obesity focus, establishing divisions in vitamins, gastrointestinal products, and women’s health. With a landmark Biocon licensing deal for GLP-1 therapies and plans to launch 30 new…